Vilon

eLife · 2024

Researchers studied how certain inhibitors affect the behavior of a protein called ERK2, which plays a role in cell signaling. They found that a specific inhibitor, Vertex-11e, can influence the protein's structure, promoting a more active state. Additionally, they identified 14 new molecules that also encourage this active state, revealing important insights into how these inhibitors work.

• Researchers found that the inhibitor Vertex-11e promotes a specific active state of the ERK2 protein.
• The study observed that this active state is linked to changes in the protein's structure and function.
• Researchers identified 14 new molecules that also select for this active state, enhancing understanding of inhibitor properties.

Journal of biomaterials science. Polymer edition · 2024

Researchers studied a new drug delivery system that combines graphene oxide with a special polymer to enhance how much medication can be loaded and released in response to certain conditions. They found that this system can also track the medication's movement within cells using its natural fluorescence, eliminating the need for additional dyes.

• Researchers observed that the combination of graphene oxide and the PEG-Glu-Lys-Glu copolymer significantly improved the drug loading rates.
• The study found that the drug delivery system allows for controlled release of medication in response to specific conditions.
• Researchers noted that the fluorescence properties of graphene oxide enable effective monitoring of drug distribution within cells.

Nucleic acids research · 2023

Researchers introduced a new method called ViLoN to better analyze patient data by integrating various molecular profiles. They found that this approach significantly improved the classification of patients with certain cancers, especially when using prior knowledge about gene functions.

• ViLoN effectively combined different types of molecular data to enhance patient stratification.
• The method showed substantial improvements in classifying patients with rectum adenocarcinoma and esophageal carcinoma.
• In smaller patient groups, ViLoN outperformed other methods by utilizing existing functional knowledge.

Voprosy onkologii · 2005

Researchers studied the effects of vilon (Lys-Glu) on tumor development in mice exposed to a chemical that can cause cancer. They found that only 14.3% of mice treated with vilon developed tumors, compared to 60% in the control group, suggesting vilon may reduce the risk of tumor formation.

• Vilon treatment resulted in a significant reduction in tumor development in mice exposed to a cancer-causing chemical.
• Only 14.3% of mice treated with vilon developed tumors, compared to 60% in the untreated control group.
• The study also noted that vilon inhibited early changes in the kidneys that could lead to cancer.

Bulletin of experimental biology and medicine · 2002

Researchers studied the effects of two compounds, Vilon and Epithalon, on gene expression in the hearts of mice. They found that both compounds significantly altered the expression of numerous genes, indicating their specific effects on heart function at the genetic level.

• Vilon changed the expression of 36 genes, while Epithalon affected 98 genes.
• Combined treatment with Vilon and Epithalon altered the expression of 144 genes.
• Epithalon alone activated the expression of 194 genes, with some changes being as much as 6.61 times higher.

Bulletin of experimental biology and medicine · 2000

Researchers observed that administering vilon (Lys-Glu) to female mice starting at six months of age increased their physical activity and endurance, extended their lifespan, and reduced the occurrence of tumors. The study also found that vilon did not negatively affect reproductive function or cause harmful effects over time.

• Vilon administration increased physical activity and endurance in mice.
• The treatment prolonged lifespan and reduced the development of tumors.
• Long-term use of vilon was found to be safe with no adverse effects on development.

International journal of peptide and protein research · 1993

Researchers developed a new method for synthesizing peptides using proteins as a support structure. They successfully created specific peptide-protein conjugates and found that these conjugates could generate targeted antibodies in rabbits, which may be useful for developing precise immune responses.

• Researchers synthesized two peptides on a protein support using a cleavable linker method.
• They obtained peptide-protein conjugates with a high number of peptide chains attached to each protein molecule.
• Immunization with one of the conjugates resulted in the production of specific antibodies in rabbits.